Development and biological evaluation of a new nanotheranostic for tuberculosis
In this study, we developed, characterized, and tested in vivo polymeric nanoparticle of ethambutol labeled with 99mTc as nanoradiopharmaceutical for early diagnosis of tuberculosis by single-photon emission computed tomography, also as a therapeutic choice. Nanoparticles were developed by double emulsification. All characterization tests were performed, as scanning electron microscopy and dynamic light scattering. The labeling process with 99mTc was performed using the direct labeling process. In vitro and in vivo assays were performed with animals and cells. The results showed that a spherical ethambutol nanoparticle with a size range of 280–300 nm was obtained. The stability test showed that the nanoparticles were well labeled with 99mTc (> 99.1%) and keep labeled over 24 h. The biodistribution assay showed that almost 18% of the nanoparticles were uptake by the lung in infected mice (male C57Bl/6) with Mycobacterium bovis BCG (4 × 105 CFU/cavity), corroborating its use as a nanodrug for tuberculosis imaging. The results for the cell assay corroborate its therapeutical effect. We developed and efficiently tested a new nanodrug that can be used for both imaging and therapy of tuberculosis, acting as a novel nanotheranostic.
KeywordsRadiopharmaceuticals Nanotechnology Smart device Infection
Technetium 99 metastable
Single-photon emission computed tomography
Roswell Park Memorial Institute medium
Dynamic light scattering
Scanning electron microscopy
National Institutes of Health
Enhanced permeability and retention
The authors would like to thank FAPERJ and CNPq for the financial support of this research.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 1.Corvino DFL, Kosmin AR. Tuberculosis, screening: StatPearls Publishing; 2017.Google Scholar
- 7.Adigun R, Bhimji SS. Tuberculosis. Treasure Island: StatPearls Publishing; 2017.Google Scholar
- 8.Roya-Pabon CL, Perez-Velez CM. Tuberculosis exposure, infection and disease in children: a systematic diagnostic approach. Pneumonia (Nathan). 2016;24:8–23.Google Scholar
- 9.Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320–30.Google Scholar
- 11.Aderibigbe BA. Metal-based nanoparticles for the treatment of infectious diseases. Molecules. 2017;18:22–7.Google Scholar
- 12.Saifullah B, Maitra A, Chrzastek A, Naeemullah B, Fakurazi S, Bhakta S, et al. Nano-formulation of Ethambutol with multifunctional Graphene oxide and magnetic nanoparticles retains its anti-tubercular activity with prospects of improving chemotherapeutic efficacy. Molecules. 2017;12:22(10).Google Scholar
- 16.Weldu Y, Asrat D, Woldeamanuel Y, Hailesilasie A. Comparative evaluation of a two-reagent cold stain method with Ziehl-Nelseen method for pulmonary tuberculosis diagnosis. BMC Res Notes. 2013;6(323):13.Google Scholar
- 19.Forbes M, Kuck NA, Peets EA. Mode of action of ethambutol. J Bacteriol. 1962;84:1099–103.Google Scholar
- 20.Kuck NA, Peets EA, Forbes M. Mode of action of ethambutol on Mycobacterium tuberculosis, strain H37R V. Am Rev Respir Dis. 1963;87:905–6.Google Scholar
- 22.Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72(4):621–7.Google Scholar